China's Pharmaceutical Market Enterprise Ranking 2023 Unveiled: Top 100 Companies and Best-Selling Drug Brands Across Eight Comprehensive Lists

With the continuous advancement of science and technology, the pharmaceutical field is developing at an accelerated pace. China's biopharmaceutical industry is steadily growing and gradually expanding, especially as it enters the post-pandemic era, where the biopharmaceutical industry has become one of the key strategic emerging industries prioritized for development by the country.

For pharmaceutical companies, R&D and sales are two indispensable core capabilities. Strong sales ability is an important guarantee for the revenue of pharmaceutical enterprises and also a crucial investment to help companies achieve a closed loop in the "R&D, production, and sales" logic. This also indicates that while the market tests the R&D strength of pharmaceutical enterprises, it simultaneously evaluates their sales capabilities.

Based on this, in order to encourage and guide the development and growth of pharmaceutical enterprises, and improve industrial concentration and market competitiveness,Yaozhi Network, in collaboration with the Organizing Committee of the Greater Health Industry (Chongqing) Expo / Shuangpin Association, has launched the "2023 China Pharmaceutical Market Pharmaceutical Enterprises Ranking" for the first time.(The detailed list is available at the end of the article) and was grandly released at the "2024 China Pharmaceutical Marketing Big Data Summit."

"2023 China Pharmaceutical Market Pharmaceutical Companies Ranking" is divided into the enterprise list and the pharmaceutical brand list.The enterprise list includes the "TOP 100 Pharmaceutical Companies in China's Pharmaceutical Market 2023" (referred to as the General List), as well as three sub-lists: the "TOP 100 Pharmaceutical Companies in China's Pharmaceutical Market (Chemical Medicine) 2023" (referred to as the Chemical Medicine List), the "TOP 100 Pharmaceutical Companies in China's Pharmaceutical Market (Traditional Chinese Medicine) 2023" (referred to as the Traditional Chinese Medicine List), and the "TOP 50 Pharmaceutical Companies in China's Pharmaceutical Market (Biological Medicine) 2023" (referred to as the Biological Medicine List).

The pharmaceutical brand rankings include the "Top 50 of the 2023 China Pharmaceutical Retail Ranking List (Chemical Drugs, Biologics)," "Top 50 of the 2023 China Pharmaceutical Retail Ranking List (Traditional Chinese Medicine)," as well as the "Top 20 in Cardio-Cerebrovascular Drug Retail 2023" and "Top 20 in Respiratory System Drug Retail 2023" (For detailed scoring criteria, please refer to the ranking rules at the end of the article: "2023 China Pharmaceutical Sales Strength Ranking List").

The list data is sourced from the Yaoke Medicine Sales Database. This list only represents the sales strength of enterprises in medical institutions and pharmacies, as well as the sales strength of pharmaceutical brands in 2023.

In the corporate rankings:AstraZeneca and Pfizer occupy the "top" and "second" positions on two lists; Shijiazhuang Yiling Pharmaceutical Co., Ltd. stands out among local pharmaceutical companies, ranking first in the Traditional Chinese Medicine list; in the biopharmaceuticals list, Qilu Pharmaceutical, a local company, rivals multinational corporations to secure the "third" position.

The top three overall rankings are respectivelyAstraZeneca, Pfizer, Yangtze River Pharmaceutical Group Co., Ltd.

The top three in the chemical pharmaceuticals ranking areAstraZeneca, Pfizer, CSPC.

The Top Three of Traditional Chinese Medicine List areShijiazhuang Yiling Pharmaceutical Co., Ltd., Taiji, CR SANJIU

The top three in the biopharmaceutical rankings are respectivelyNovo Nordisk, Roche, Qilu Pharmaceutical.

In the pharmaceutical brand rankings：Kewe® Oseltamivir Phosphate Granules and Tongrentang® Angong Niuhuang Pills stood out among a group of heavyweight drugs from multinational corporations (MNCs), topping the "Top 50 China Pharmaceutical Retail Rankings (Chemical & Biologic Drugs) 2023" and the "Top 20 Cardio-Cerebrovascular Drug Retail Rankings 2023," respectively. Dong'e Ejiao® Ejiao showcased its unique charm, dominating the "Top 50 China Pharmaceutical Retail Rankings (Traditional Chinese Medicine) 2023." 999® Ganmao Ling Granules, with their excellent efficacy and broad applicability, took the lead in the "Top 20 Respiratory Drug Retail Rankings 2023."

Top Three of "2023 China Pharmaceutical Retail Ranking List (Chemical Drugs, Biologics) TOP50" are:Kewe® Oseltamivir Phosphate Granules, Lipitor® Atorvastatin Calcium Tablets, Viagra® Sildenafil Citrate Tablets.

Top Three of "2023 China Pharmaceutical Retail Ranking (TCM) TOP50" are:Dong'e Ejiao® Ejiao, 999® Ganmao Ling Granules, Taiji® Huoxiang Zhengqi Oral Liquid.

Top 3 of "2023 Retail Top 20 for Cardiovascular and Cerebrovascular Drugs" are:Tong Ren Tang® Angong Niuhuang Pills, Lipitor® Atorvastatin Calcium Tablets, Bayxin Tong® Nifedipine Controlled-Release Tablets.

Top 20 Respiratory Medications Retail Rankings 2023999® Cold Remedy Granules, Yangtze River® Lanqin Oral Liquid, Kyoto Nichi-in® Honey-Processed Fritillary Loquat Syrup.

1. Ranking Rules for the 2023 China Pharmaceutical Market Pharmaceutical Companies Ranking

• Overall Ranking: Ranking of enterprises based on their sales revenue of pharmaceuticals in medical institutions and pharmacies.

  
  

• Chemical Pharmaceuticals Ranking: Only the sales revenue of enterprises' chemical pharmaceuticals in medical institutions and pharmacies is counted, and enterprises are ranked based on their sales revenue.

  
  

• TCM List: Only the sales revenue of enterprises' TCM in medical institutions and pharmacies is counted, and then enterprises are ranked based on the sales revenue.

  
  

• Biological Medicine Ranking: Only the sales of enterprises' biological medicines (biological products) in medical institutions and pharmacies are counted, and enterprises are ranked based on their sales.

2. Ranking Rules for Pharmaceutical Brand Rankings

Ranking based on the sales performance of individual drugs in pharmacies.

3. Special Instructions

Enterprise Statistical Rules Description:

• The enterprise rankings are usually compiled based on group companies. However, for large-scale listed subsidiaries with significant sales, they are ranked separately.

  
  

• This list reflects the sales performance of companies in the Chinese mainland market, including foreign enterprises.

The Expert Committee of the 2023 China Pharmaceutical Market Pharmaceutical Companies Ranking adheres to the principles of professionalism, dedication, honesty, and responsibility, striving to ensure fairness and impartiality. However, there may be some shortcomings, for which we kindly ask for your understanding.

Editor: Pea Shooter

Disclaimer: The views expressed in this article represent the author's personal opinions and do not reflect the position of Pharma Intelligence Network. We welcome exchanges and additional insights in the comment section. If you wish to reproduce this article, please be sure to credit the author and source. For any issues related to the content, copyright, or other aspects of the article, please leave a message on this platform, and we will address it promptly.